Bio-Rad Laboratories A (BIO) Fundamental Analysis: Revenue, Earnings & Valuation

0.05 / 10

Underperform

Fundamental analysis rates BIO as Underperform, scoring only 0.1/10. Strong points include Net‑income‑Revenue and high profit margins, but Asset‑MV and Revenue‑MV are weak, dragging performance. Overall, the company’s financial health is challenged, suggesting limited upside.

Analysis Checks(7/10)

Revenue-MV

Value-0.23

Score0/3

Weight635.70%

1M Return-9.81%

Net cash flow from operating activities / Operating revenue (%)

Value20.60

Score3/3

Weight-167.12%

1M Return1.62%

Profit-MV

Value1.47

Score2/3

Weight93.04%

1M Return-1.01%

Net income-Revenue

Value2.14

Score3/3

Weight-663.93%

1M Return5.20%

Net profit margin (%)

Value29.42

Score3/3

Weight-110.93%

1M Return1.08%

Cash-UP

Value0.13

Score1/3

Weight508.44%

1M Return-6.49%

Net cash flow from operating activities / Total liabilities (%)

Value0.17

Score2/3

Weight-70.56%

1M Return0.68%

EBIT / Total operating revenue (%)

Value40.43

Score3/3

Weight-147.67%

1M Return1.39%

Asset-MV

Value-0.55

Score1/3

Weight133.97%

1M Return-2.84%

Net profit / Total operating revenue (%)

Value29.42

Score3/3

Weight-110.93%

1M Return1.08%

Is BIO fundamentally strong?

BIO scores 0.05/10 on fundamentals and holds a Premium valuation at present. Backed by its 10.84% ROE, 29.42% net margin, 10.01 P/E ratio, 1.02 P/B ratio, and 142.64% earnings growth, these metrics solidify its Underperform investment rating.